Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Center Hospital, Montpellier, France
Findings from France, Spain and Japan in lung cancer provide new insights
July 4th, 2006
Reports from France, Spain and Japan highlight recent research in lung cancer. Study 1: The risk of death in lung cancer patients could be decreased with a platinum-based chemotherapy doublet. According to a study from France, "Non-platinum regimens have been proposed as an alternative to the platinum-based combinations for treatment of advanced non-small cell lung cancer. However, conflicting results were reported. Meta-analysis of phase III trials randomizing platinum-based versus non-platinum combinations as first-line chemotherapy with 1-year survival rate as a primary endpoint [was conducted]." "Fourteen trials have been...
Source: Pharma Law Weekly (2006-07-04)
|
